Pharmacyclics Llc patent expiration
1. Imbruvica patent expiration
IMBRUVICA's oppositions filed in EPO
IMBRUVICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8697711 | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US9181257 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8957079 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8735403 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US7514444 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8008309 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(3 years from now) | |
| US10125140 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10106548 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9725455 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9296753 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754091 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8952015 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8703780 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8476284 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8497277 | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(2 years from now) | |
| US8563563 | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(2 years from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(2 years from now) | |
|
US8563563 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(3 years from now) | |
|
US8008309 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(3 years from now) | |
| US10004746 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10016435 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9125889 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US8999999 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9801881 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US9801883 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10751342 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US11672803 | PHARMACYCLICS LLC | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US8754090 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10478439 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9814721 | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US10653696 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(7 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(7 years from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(7 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(7 years from now) | |
| US9713617 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10752634 | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10294232 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10961251 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US10294231 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(8 years from now) | |
| US9540382 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(8 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US9540382 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(9 years from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(9 years from now) | |
| US9795604 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(10 years from now) | |
| US10463668 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(10 years from now) | |
| US10695350 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(10 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(10 years from now) | |
|
US9795604 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(10 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(10 years from now) | |
| US9655857 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
| US10010507 | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
| US10828259 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
| US10213386 | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(11 years from now) | |
|
US10213386 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
|
US9655857 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
|
US10828259 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
|
US10010507 (Pediatric) | PHARMACYCLICS LLC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| ODE*(ODE*) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia; Treatment of small lymphocytic lymphoma; Treatment of waldenstrom's macroglobulinemia; Treatment o...
Dosage: TABLET; SUSPENSION; CAPSULE
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
